The importance of health economics in a world of proportionally increasing scarce resources by Ferraz, Marcos Bosi
Marcos Bosi Ferraz
The importance of health economics in a world
of proportionally increasing scarce resources
Divisiio de Reumatologia da Universidade
Federal de Siio Paulo
In all countries of the world, increasing pressures on scarce
resources have meant that all investments, inside and outside the
health sector, have come under closer scrutiny. This in turn has
led to an increased interest in analytical approaches to the evalua-
tion of alternative strategies from an economic prospective.
Traditionally, 3 issues have been adressed in the evaluation
of health care or pharmaceutical agents:
1.The first deals with safety; is it harmful to people? Toxi-
cology, clinical and post-marketing surveillance studies are used
to address this question.
2. The second deals with efficacy: can a particular
therapeutical intervention work? For an example, under ideal con-
ditions when a patient is given the correct dose, at the correct time,
over an appropriate period, does a therapeutic intervention have
the desired effect?
3. The third set deals with effectiveness: does the interven-
tion (drug) work in the real world when patients use it on a day-to-
day basis according to their own perception of instructions given
to them by their physicians?
To these traditional analyses economists and health econo-
mists have recently added a new area of evaluation, the question
of efficiency. The essence of this new perspective is expressed in
the question "Are we getting the best outcome for the money we
are spending?
Economic assessment is about choosing between alterna-
tive uses of resourses. In doing so, both of the costs and the out-
comes of investments are considered. As the basic assumption of
any analysis is that there are not, and never will be, enough
resourses to satisfy all needs completely trade offs have to be made
- where to invest and where not to.
Economic analysis can be conceived in 3 dimensions. Each
dimension describes an important aspect of the analysis:
1.The design of the analysis may be of 4 types: cost-mini-
mization, cost-benefit, cost-effectiveness or cost-utility; if all con-
sequences are essentially identical between the drug and relevant
comparators, a cost-minimization analysis is adequate; In other
instances one of the other three economic analysis is required. In
cost-utility analysis the quantity of life improvement (mortality)
and the health related quality of life improvement ~re combined
into a single metric (QALYs). This combination has the advan-
tage of permitting broad comparisons between the performed
analysis and other interventions the health care sector. In cost-
benefit analysis the health improvement is translated into an equiva-
lent monetary value. Two approaches can be used to value the
health improvement: a. Human capital, and; b. Contingent valua-
tion using willingness to pay.
2. Different points of view may be taken in the analysis,
those of society, the prayer, the provider, or the patient; All studies
should report from a comprehensive societal perspective. Also,
the perspective should be broken down into those of other rel-
evant viewpoints, including that of the p~imary decision maker.
3. Different types of costs and benefits may be included:
direct, indirect and intangible. Resourses used in each interven-
tion being compared should be described first in natural (non-
monetary) units. When possible standard cost values should be
used in costing out resourse utilization. Whenever possible, indi-
rect costs should be documented and reported. Costs items are
included or excluded from the analysis depending on the view-
point adopted.
Finnaly, with the growing international literature in economic
evaluation and the rapid international apread of health techno-
logic, there is a need to undertake, or at least, interpret economic
evaluations on the internationalleveI. Health care decision mak-
ers, especially in those countries having limited resourses for health
technology assessment (the case in most, if not all developing coun-
tries) may wish to reinterpret in their own setting the results of an
economic evaluation that was done elsewhere.
However, a number of factors limit the generalizability of
economic data and extrapolation of results is an issue not only
between but also within countries. Among the factors that are likely
to differ from place to place, it can be cited: 1. Demography and
Epydemiology of Disease. 2. Health Care Resourses Distribution
and Availability. 3. Variation in Clinical Pratice. 4. Incentives to
professionals and institutions. 5. Relative Price Levels.
The few cross-national economic studies undertaken to date
indicate that differences in these factors do impact the ecomomic
evaluation of health technologies. As a result, whenever pos-
sible, both economic and clinical data should be gathered in
each country.
In conclusion, the ultimate aim of economic evaluation
is to assist decision making and not to replace decision mak-
ing.
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